Skip to main content
. 2016 Aug 18;82(5):1351–1357. doi: 10.1111/bcp.13062

Figure 2.

Figure 2

The blood pressure (BP)‐lowering potential of sulodexide depends on albuminuria severity. (A) Regression lines and 95% confidence intervals (CIs) of the analysis of covariance (ANCOVA) demonstrating the significant interaction (P = 0.001) between the baseline urine albumin‐to‐creatinine ratio (UACR) and treatment arms (placebo vs. sulodexide). The regression line slopes of placebo (P < 0.001) and sulodexide (P < 0.001) were both significantly different from zero. (B) Quantitative analysis of the results of the ANCOVA, showing that subjects with an UACR >1000 mg g–1 benefit most from sulodexide treatment in terms of BP (mean and 95% CI). Sulodexide resulted in a 2.0 mmHg (95% CI −2.6, −1.3) systolic BP (SBP) reduction, while placebo increased SBP by 2.5 mmHg (95% CI 1.9, 3.3). In the group with an UACR between 300–1000 mg g–1, sulodexide decreased BP by 0.8 mmHg (95% CI −1.8, 0.2) and placebo increased BP by 1.6 mmHg (95% CI 0.6, 2.5), while subjects with an UACR <300 mg g–1 had an identical BP response (0.2 mmHg, 95% CI −0.5, 0.8; P = 0.60)